You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

338 Results
Document
May 2019
Guidelines and Advice
Status: In-Review
ID: GL 2-24
May 2019
Document
Jul 2019
Document
Jul 2019
Cancer facts
Sep 2019
Document
Sep 2019
Document
Sep 2019
Document
Oct 2019
Document
Oct 2019
Document
Jan 2020
Drug
Other Name(s): Unituxin®
Quick Link(s):
Drug Monograph
Jun 2023
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    darolutamide - For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
darolutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024

Pages